In preclinical models, researchers are exploring effects on endothelial function, blood pressure, lipid profiles, and inflammatory biomarkers
Data Privacy Cookie Privacy Cookie Settings
Emerging evidence suggests that GIPR antagonism could improve the tolerability of agonists by reducing nausea, according to a 2025 study 9
Nonetheless, these therapies possess drawbacks, notably the considerable toxicity linked to NSAIDs, which may result in gastrointestinal complications and reduced renal blood flow [12,13]
coli co-crystal structure (residues Trp 155 , Lys 179 , Ser 233 and Glu 385 )